Biogen works to discover and develop treatments for people living with serious neurological and neurodegenerative diseases. Today, Biogen has a portfolio of medicines to treat relapsing multiple sclerosis (MS). We are the only company that offers five treatments for relapsing forms of MS.
Our commitment to MS fuels our passion to provide even more treatment options to people living with MS around the world. For over two decades, we’ve worked hard to develop a range of therapies to treat this disease. In fact, year after year, we reinvest a significant amount of our earnings into product research and development to find new and different ways of treating relapsing forms of MS.
Aside from all the medications we offer for relapsing MS, Biogen has thousands of amazing employees. Many of us have a personal connection to MS. We may be living with this disease or know or love someone who has MS.
The process of developing a new treatment is a marathon not a sprint. There are three key stages before a new treatment becomes available. Hover over each stage to learn more.
During this phase, researchers learn how the disease impacts the body and search for ways to fight the problem
Before a new drug can be approved, it goes through extensive clinical trials to determine if it’s safe and effective. There are three distinct phases. At each successive phase, the drug is tested with larger groups of people.
Once a treatment is approved by the U.S. Food & Drug Administration (FDA), teams work to get it into patients’ hands by preparing the medicine for distribution. There is also ongoing monitoring for safety and unexpected side effects.